Purchase this article with an account.
J. Lee, G. Seong, S. Kim, S. Han, H. Lee, O. Kwon; Evaluation of Clinical Effects of a Purified High–Dose Anthocyanoside Oligomer . Invest. Ophthalmol. Vis. Sci. 2005;46(13):5624.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To evaluate the benefit of taking purified high–dose anthocyanoside oligomer for improving nocturnal visual function and clinical symptoms. Methods: We performed a randomized, double–blind, placebo–controlled trial in low to moderate myopia subjects. The subjects who were included in this study had a refractive error with asthenopia between –1.00 and –8.00 diopters in both eyes. A total of 60 people who qualified the criteria above were enrolled and the subjects were instructed to take purified high–dose anthocyanoside oligomer or placebo twice daily for a period of 4 weeks. Age, refractive error, and morphoscopic contrast sensitivity (MCS) were matched between placebo group and treatment group. The enrolled subjects were investigated for nocturnal vision performance by MCS and clinical symptoms at their first visit and re–evaluated at post–intervention (unpaired t–test and Fisher's exact test) Results: Four weeks after the study, 22 subjects (73.3%) of anthocyanoside group showed symptomatic improvement compared to the subjects of placebo group (p=0.000). Contrast sensitivity levels, according to each cycles/degree (CPD) before and after drug taking, were also significantly improved in anthocyanoside group. The mean MCS change of anthocyanoside group was 2.41±1.91, compared to –0.40±2.47 of the placebo group (p=0.000). In all levels of CPD, MCS changes in anthocyanoside group showed significant improvement compared to the placebo group (p<0.05). Conclusions: Our results show that purified high–dose anthocyanoside oligomer may improve the subjective symptoms and objective MCS results in myopia subjects with asthenopia.
This PDF is available to Subscribers Only